Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Activated Stromal Cells Transfer Mitochondria to Rescue Acute Lymphoblastic Leukaemia Cells from Oxidative Stress.

Burt R, Dey A, Aref S, Aguiar M, Akarca A, Bailey K, Day W, Hooper S, Kirkwood A, Kirschner K, Lee S, Lo Celso C, Manji J, Mansour MR, Marafioti T, Mitchell RJ, Muirhead RC, Ng KCY, Pospori C, Puccio I, Zuborne-Alapi K, Sahai E, Fielding AK.

Blood. 2019 Sep 9. pii: blood.2019001398. doi: 10.1182/blood.2019001398. [Epub ahead of print]

PMID:
31501154
2.

The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.

Armenteros-Monterroso E, Zhao L, Gasparoli L, Brooks T, Pearce K, Mansour MR, Martens JHA, de Boer J, Williams O.

Leukemia. 2019 May 28. doi: 10.1038/s41375-019-0495-8. [Epub ahead of print]

PMID:
31138842
3.

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish.

Gjini E, Jing CB, Nguyen AT, Reyon D, Gans E, Kesarsing M, Peterson J, Pozdnyakova O, Rodig SJ, Mansour MR, Joung K, Look AT.

Dis Model Mech. 2019 May 7;12(5). pii: dmm035790. doi: 10.1242/dmm.035790.

4.

JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.

Mansour MR, He S, Li Z, Lobbardi R, Abraham BJ, Hug C, Rahman S, Leon TE, Kuang YY, Zimmerman MW, Blonquist T, Gjini E, Gutierrez A, Tang Q, Garcia-Perez L, Pike-Overzet K, Anders L, Berezovskaya A, Zhou Y, Zon LI, Neuberg D, Fielding AK, Staal FJT, Langenau DM, Sanda T, Young RA, Look AT.

J Exp Med. 2018 Jul 2;215(7):1929-1945. doi: 10.1084/jem.20170484. Epub 2018 Jun 25.

5.

Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial.

Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, Patrick K, Hancock J, Samarasinghe S, Linch DC, Moorman AV, Goulden N, Vora A, Mansour MR.

Haematologica. 2018 Jul;103(7):e288-e292. doi: 10.3324/haematol.2017.185801. Epub 2018 Mar 8. No abstract available.

6.

Corrigendum: Small genomic insertions form enhancers that misregulate oncogenes.

Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, Weichert-Leahey N, Rahman S, Liu Y, Etchin J, Li B, Shen S, Lee TI, Zhang J, Look AT, Mansour MR, Young RA.

Nat Commun. 2017 Jun 1;8:15797. doi: 10.1038/ncomms15797.

7.

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.

Rahman S, Magnussen M, León TE, Farah N, Li Z, Abraham BJ, Alapi KZ, Mitchell RJ, Naughton T, Fielding AK, Pizzey A, Bustraan S, Allen C, Popa T, Pike-Overzet K, Garcia-Perez L, Gale RE, Linch DC, Staal FJT, Young RA, Look AT, Mansour MR.

Blood. 2017 Jun 15;129(24):3221-3226. doi: 10.1182/blood-2016-09-742148. Epub 2017 Mar 7.

8.

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.

Li Z, Abraham BJ, Berezovskaya A, Farah N, Liu Y, Leon T, Fielding A, Tan SH, Sanda T, Weintraub AS, Li B, Shen S, Zhang J, Mansour MR, Young RA, Look AT.

Leukemia. 2017 Oct;31(10):2057-2064. doi: 10.1038/leu.2017.75. Epub 2017 Mar 6.

9.

Small genomic insertions form enhancers that misregulate oncogenes.

Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, Weichert-Leahey N, Rahman S, Liu Y, Etchin J, Li B, Shen S, Lee TI, Zhang J, Look AT, Mansour MR, Young RA.

Nat Commun. 2017 Feb 9;8:14385. doi: 10.1038/ncomms14385.

10.

Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain.

He S, Mansour MR, Zimmerman MW, Ki DH, Layden HM, Akahane K, Gjini E, de Groh ED, Perez-Atayde AR, Zhu S, Epstein JA, Look AT.

Elife. 2016 Apr 27;5. pii: e14713. doi: 10.7554/eLife.14713.

11.

The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis.

Anderson NM, Li D, Peng HL, Laroche FJ, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, Feng H.

Leukemia. 2016 Jun;30(6):1365-74. doi: 10.1038/leu.2016.26. Epub 2016 Feb 15.

12.

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.

Akahane K, Sanda T, Mansour MR, Radimerski T, DeAngelo DJ, Weinstock DM, Look AT.

Leukemia. 2016 Jan;30(1):219-28. doi: 10.1038/leu.2015.222. Epub 2015 Aug 12.

13.

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.

Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT.

Leukemia. 2016 Jan;30(1):190-9. doi: 10.1038/leu.2015.194. Epub 2015 Jul 23.

14.

Effects of dietary onion (Allium cepa) powder on growth, innate immune response and hemato-biochemical parameters of beluga (Huso huso Linnaeus, 1754) juvenile.

Akrami R, Gharaei A, Mansour MR, Galeshi A.

Fish Shellfish Immunol. 2015 Aug;45(2):828-34. doi: 10.1016/j.fsi.2015.06.005. Epub 2015 Jun 8.

PMID:
26067169
15.

A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.

Gjini E, Mansour MR, Sander JD, Moritz N, Nguyen AT, Kesarsing M, Gans E, He S, Chen S, Ko M, Kuang YY, Yang S, Zhou Y, Rodig S, Zon LI, Joung JK, Rao A, Look AT.

Mol Cell Biol. 2015 Mar;35(5):789-804. doi: 10.1128/MCB.00971-14. Epub 2014 Dec 15.

16.

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT.

Science. 2014 Dec 12;346(6215):1373-7. doi: 10.1126/science.1259037. Epub 2014 Nov 13.

17.

Cyclin C is a haploinsufficient tumour suppressor.

Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, Gutierrez A, Ordureau A, Otto T, Kreslavsky T, Baitsch L, Bury L, Meyer CA, Ke N, Mulry KA, Kluk MJ, Roy M, Kim S, Zhang X, Geng Y, Zagozdzon A, Jenkinson S, Gale RE, Linch DC, Zhao JJ, Mullighan CG, Harper JW, Aster JC, Aifantis I, von Boehmer H, Gygi SP, Wei W, Look AT, Sicinski P.

Nat Cell Biol. 2014 Nov;16(11):1080-91. doi: 10.1038/ncb3046. Epub 2014 Oct 26.

18.

Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT.

Br J Haematol. 2015 Jan;168(2):230-8. doi: 10.1111/bjh.13115. Epub 2014 Sep 26.

19.

Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.

Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N.

Gastroenterology. 2014 Oct;147(4):882-892.e8. doi: 10.1053/j.gastro.2014.06.041. Epub 2014 Jul 3.

20.

Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia.

Shochat C, Tal N, Gryshkova V, Birger Y, Bandapalli OR, Cazzaniga G, Gershman N, Kulozik AE, Biondi A, Mansour MR, Twizere JC, Muckenthaler MU, Ben-Tal N, Constantinescu SN, Bercovich D, Izraeli S.

Blood. 2014 Jul 3;124(1):106-10. doi: 10.1182/blood-2013-10-529685. Epub 2014 May 1.

21.

Notch signaling: switching an oncogene to a tumor suppressor.

Lobry C, Oh P, Mansour MR, Look AT, Aifantis I.

Blood. 2014 Apr 17;123(16):2451-9. doi: 10.1182/blood-2013-08-355818. Epub 2014 Mar 7. Review.

22.

BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.

Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H.

Leukemia. 2014 May;28(5):1145-8. doi: 10.1038/leu.2013.377. Epub 2013 Dec 17. No abstract available.

23.

The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.

Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, von Boehmer H, Young RA, Look AT.

J Exp Med. 2013 Jul 29;210(8):1545-57. doi: 10.1084/jem.20122516. Epub 2013 Jul 15.

24.

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A.

Br J Haematol. 2013 Apr;161(1):117-27. doi: 10.1111/bjh.12231. Epub 2013 Feb 4.

25.

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.

Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE, Khwaja A.

Leukemia. 2013 Mar;27(3):650-60. doi: 10.1038/leu.2012.285. Epub 2012 Oct 5.

PMID:
23038273
26.

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.

Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, Look AT.

Leukemia. 2013 Jan;27(1):66-74. doi: 10.1038/leu.2012.219. Epub 2012 Jul 31.

27.

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.

Jenkinson S, Koo K, Mansour MR, Goulden N, Vora A, Mitchell C, Wade R, Richards S, Hancock J, Moorman AV, Linch DC, Gale RE.

Leukemia. 2013 Jan;27(1):41-7. doi: 10.1038/leu.2012.176. Epub 2012 Jul 3.

PMID:
22814294
28.

Discovery of a secreted tumor suppressor provides a promising therapeutic strategy for follicular lymphoma.

Mansour MR, Look AT.

Cancer Cell. 2011 Nov 15;20(5):559-61. doi: 10.1016/j.ccr.2011.10.027.

29.

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM.

Blood. 2009 Dec 10;114(25):5136-45. doi: 10.1182/blood-2009-08-231217.

30.

Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.

Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC.

J Clin Oncol. 2009 Sep 10;27(26):4352-6. doi: 10.1200/JCO.2009.22.0996. Epub 2009 Jul 27.

31.

WT1 mutations in T-ALL.

Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA.

Blood. 2009 Jul 30;114(5):1038-45. doi: 10.1182/blood-2008-12-192039. Epub 2009 Jun 3.

32.

Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma.

Mansour MR.

Expert Rev Hematol. 2009 Apr;2(2):133-6. doi: 10.1586/ehm.09.3.

PMID:
21083447
33.

Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.

Gordon WR, Roy M, Vardar-Ulu D, Garfinkel M, Mansour MR, Aster JC, Blacklow SC.

Blood. 2009 Apr 30;113(18):4381-90. doi: 10.1182/blood-2008-08-174748. Epub 2008 Dec 15.

34.

Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.

Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von Kalle C, Gaspar HB, Thrasher AJ.

J Clin Invest. 2008 Sep;118(9):3143-50. doi: 10.1172/JCI35798.

35.

Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia.

Mansour MR, Duke V, Foroni L, Patel B, Allen CG, Ancliff PJ, Gale RE, Linch DC.

Clin Cancer Res. 2007 Dec 1;13(23):6964-9.

36.

A role for aberrant Notch signaling in acute myeloid leukemia?

Mansour MR.

Leuk Lymphoma. 2006 Nov;47(11):2280-1. No abstract available.

PMID:
17107898
37.

High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia.

Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE.

Leukemia. 2006 Mar;20(3):537-9. No abstract available.

PMID:
16424867
38.

Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma.

Mansour MR, Dogan A, Morris EC, Khwaja A, Linch DC, Mackinnon S, Peggs KS.

Bone Marrow Transplant. 2005 May;35(9):931-4. No abstract available.

PMID:
15778731
39.

Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors.

Havlik R, Sbisà E, Tullo A, Kelly MD, Mitry RR, Jiao LR, Mansour MR, Honda K, Habib NA.

Hepatogastroenterology. 2000 Jul-Aug;47(34):927-31.

PMID:
11020850
40.

Gene therapy for liver tumours.

Mitry RR, Mansour MR, Havlík R, Habib NA.

Adv Exp Med Biol. 2000;465:193-205. Review. No abstract available.

PMID:
10810627
41.

p53 Plasmid Preparation and Techniques for Analysis of Gene Transfer and Expression.

Mitry RR, Kelly MD, Zhao J, Negishi S, Mansour MR, Habib NA.

Methods Mol Med. 2000;45:207-20. doi: 10.1385/1-59259-079-9:207.

PMID:
21341059

Supplemental Content

Loading ...
Support Center